# Eigen Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eigen-therapeutics

- Industry: Biotechnology
- Headquarters: Redwood City, US
- Website: www.eigentx.com
- Total disclosed funding: $7M
- Latest round: Seed (Dec 8, 2022)
- Investors on record: 5

## About

Based in California, US, and co-founded by Transon Nguyen (CEO) and Kamran Ali (CTO) in 2021, Eigen Therapeutics Inc. operates as a biotechnology company focused on priming therapies that make cancer cells more visible. In December 2022, the firm raised USD 7 million in seed funding led by investor First Round Capital, with participation from other investors Bioverge, Builders VC, First Round Capital, etc. 

The company is working on the development of co-therapies by modulating the expression of the target cell to make cancer cells or tumors more visible and vulnerable to treatment and healthy cells more resilient to treatment. Eigen utilizes machine learning, robotics, and its custom-developed lab operations software to carry out its biology experiments.

The company plans to utilize its December 2022 funding to develop priming therapies initially focused on hematological malignancies.

## Funding rounds

- Seed, Dec 8, 2022, $7M — First Round Capital, Alumni Ventures Group, Builders VC, Bioverge, Hawktail

## Investors

- First Round Capital (https://capitalatlas.ai/funds/first-round-capital) — Seed
- Alumni Ventures Group (https://capitalatlas.ai/funds/alumni-ventures-group) — Seed
- Builders VC (https://capitalatlas.ai/funds/builders-vc) — Seed
- Bioverge (https://capitalatlas.ai/funds/bioverge) — Seed
- Hawktail (https://capitalatlas.ai/funds/hawktail) — Seed